A modified relaxin polypeptide comprising a non-naturally encoded amino acid, wherein:n(a) the relaxin polypeptide comprises a relaxin A chain polypeptide and a relaxin B chain polypeptide, wherein said relaxin A chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 4, and said relaxin B chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 5 or SEQ ID NO: 6, and said non-naturally encoded amino acid is substituted in said A chain polypeptide at residue 1; and(b) the non-naturally encoded amino acid is linked to a linker, polymer, or biologically active molecule, wherein said non-naturally encoded amino acid comprises a first functional group and the linker, polymer, or biologically active molecule comprises a second functional group, wherein the first functional group and second functional group are not identical and each comprise a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group, and the resultant covalent linkage created by the reaction of the first and second functional groups comprises an oxime linkage or a triazole.
›2.↳ 1The modified relaxin polypeptide of claim 1, wherein said linker, polymer, or biologically active molecule comprises poly (ethylene glycol).d2
The modified relaxin polypeptide of claim 1, wherein said linker, polymer, or biologically active molecule comprises poly (ethylene glycol).
›3.↳ 1The modified relaxin polypeptide of claim 1, wherein said relaxin A chain polypeptide has the sequence of SEQ ID NO: 4 containing said substitution of…d2
The modified relaxin polypeptide of claim 1, wherein said relaxin A chain polypeptide has the sequence of SEQ ID NO: 4 containing said substitution of said non-naturally occurring amino acid at residue 1.
›4.↳ 1The modified relaxin polypeptide of claim 1, wherein said relaxin B chain polypeptide has the sequence of SEQ ID NO: 5 or SEQ ID NO: 6.d2
The modified relaxin polypeptide of claim 1, wherein said relaxin B chain polypeptide has the sequence of SEQ ID NO: 5 or SEQ ID NO: 6.
›5.↳ 1The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid is a phenylalanine analog or derivative.d2
The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid is a phenylalanine analog or derivative.
›6.↳ 1The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid has the structure:d2
The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid has the structure:
›7.↳ 1The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine or para-azido-L-phenyl…d2
The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine or para-azido-L-phenylalanine.
›8.↳ 1The modified relaxin polypeptide of claim 1, wherein (i) the first functional group on the non-naturally encoded amino acid is a carbonyl moiety and t…d2
The modified relaxin polypeptide of claim 1, wherein (i) the first functional group on the non-naturally encoded amino acid is a carbonyl moiety and the second functional group contained on the linker, polymer, or biologically active molecule is an aminooxy moiety, and the resultant covalent linkage created by the reaction of the first and second functional groups is an oxime linkage; or (ii) the first functional group on the non-naturally encoded amino acid is an azide moiety and the second functional group contained on the linker, polymer, or biologically active molecule is an alkyne moiety, and the resultant covalent linkage created by the reaction of the first and second functional groups comprises a triazole linkage.
›9.↳ 1The modified relaxin polypeptide of claim 1, wherein said modified relaxin polypeptide is recombinant, is produced in a eukaryotic host cell, is produ…d2
The modified relaxin polypeptide of claim 1, wherein said modified relaxin polypeptide is recombinant, is produced in a eukaryotic host cell, is produced in a non-eukaryotic host cell, or is produced by in vitro translation.
›10.↳ 1The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid is linked to a polymer.d2+2
The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid is linked to a polymer.
›11.↳ 10The modified relaxin polypeptide of claim 10, wherein said polymer is a water soluble polymer.d3
The modified relaxin polypeptide of claim 10, wherein said polymer is a water soluble polymer.
›12.↳ 10The modified relaxin polypeptide of claim 10, wherein the polymer is an oligosaccharide.d3
The modified relaxin polypeptide of claim 10, wherein the polymer is an oligosaccharide.
›13.↳ 1The modified relaxin polypeptide of claim 1, wherein said non-naturally encoded amino acid is linked to a polymer comprising poly(ethylene glycol) hav…d2+3
The modified relaxin polypeptide of claim 1, wherein said non-naturally encoded amino acid is linked to a polymer comprising poly(ethylene glycol) having an average molecular weight of between about 0.1 kDa and about 100 kDa.
›14.↳ 13The modified relaxin polypeptide of claim 13, wherein the poly(ethylene glycol) moiety has an average molecular weight of between about 1 kDa and abou…d3
The modified relaxin polypeptide of claim 13, wherein the poly(ethylene glycol) moiety has an average molecular weight of between about 1 kDa and about 40 kDa.
›15.↳ 13The modified relaxin polypeptide of claim 13, wherein the poly(ethylene glycol) moiety has an average molecular weight of between about 5 kDa and abou…d3
The modified relaxin polypeptide of claim 13, wherein the poly(ethylene glycol) moiety has an average molecular weight of between about 5 kDa and about 40 kDa.
›16.↳ 13The modified relaxin polypeptide of claim 13, wherein the poly(ethylene glycol) moiety has an average molecular weight of about 20 kDa.d3
The modified relaxin polypeptide of claim 13, wherein the poly(ethylene glycol) moiety has an average molecular weight of about 20 kDa.
›17.↳ 1The modified relaxin polypeptide of claim 1, wherein the modified relaxin polypeptide is therapeutically effective to decrease vasoconstriction, incre…d2
The modified relaxin polypeptide of claim 1, wherein the modified relaxin polypeptide is therapeutically effective to decrease vasoconstriction, increase nitric oxide (NO) production, decrease platelet aggregation, decrease hypertrophy, decrease CF-stimulated protein synthesis, treat angiotensin-II (AngII)-mediated vasoconstriction, treat endothelin-1 (ET-1)-mediated vasoconstriction, or increase ANP expression, or retains the effect of the wild-type relaxin polypeptide of SEQ ID NO: 1 on urine output, plasma BUN, ad libitum water intake, plasma sodium, or plasma osmolarity.
›18.↳ 1The modified relaxin polypeptide of claim 1, wherein the modified relaxin polypeptide exhibits an increased in vivo half-life relative to the human re…d2+1
The modified relaxin polypeptide of claim 1, wherein the modified relaxin polypeptide exhibits an increased in vivo half-life relative to the human relaxin polypeptide of SEQ ID NO: 1.
›19.↳ 18The modified relaxin polypeptide of claim 18, wherein the half-life is increased by an amount selected from at least 2-fold 3-fold, 4-fold, 5-fold or …d3
The modified relaxin polypeptide of claim 18, wherein the half-life is increased by an amount selected from at least 2-fold 3-fold, 4-fold, 5-fold or 10-fold.
›20.↳ 1The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid is selected from a para-substituted, ortho-substituted, or m…d2
The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid is selected from a para-substituted, ortho-substituted, or meta-substituted phenylalanine comprising a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group.
›21.↳ 1The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid is para-acetyl-L-phenylalanine.d2
The modified relaxin polypeptide of claim 1, wherein the non-naturally encoded amino acid is para-acetyl-L-phenylalanine.